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To the Editor:
Prof. Kitson’s comments give us the opportunity to clarify some
issues that were not completely dealt with in our manuscript.
In the study we reported a link between fructose intake and
the severity of liver ﬁbrosis in a cohort of Italian patients with
genotype 1 chronic hepatitis C (CHC) [1], with an association
found for industrial, but not for fruit fructose intake. Our results
were in keeping with data already reported in patients with non-
alcoholic fatty liver disease [2,3].
Prof. Kitson and his colleagues question ﬁrstly the appropri-
ateness of using a web-based calculator of U.S. origin
(www.healthdiet.us/fructose) to assess fructose intake in the
Italian population, due to a presumed much lower fructose
consumption in the latter. Actually, we considered industrial
fructose as any amount of fructose derived from food sources
containing high fructose corn syrup (beverages like soft drink
and fruit juices, processed foods like fast-food, especially when
enriched with industrial sauces). The U.S. database for the cal-
culation of fructose intake is most likely valid also for use in
Italian patients, since the majority of foods and beverages with
added fructose are produced by multinational companies, and
the concentration of fructose does not change among countries.
In addition, our data on fructose consumption are in keeping
with another Italian report [4]. Prof. Kitson and colleagues also
question the validity of a three-day food diary. It has been
reported that a three-day diary record correlates closely with
a longer 9-day diary [5], providing a solid dietary assessment.
In a cross-sectional analysis no inference can be made regard-
ing a possible causal relationship, but this possibility may
be postulated. We have simply described the positive associa-
tion between industrial fructose and advanced ﬁbrosis, but
the two conditions might also share common pathogenic
mechanisms.
As a second point, our study was performed in an Italian pop-
ulation, not in an Australian or U.S. population, where much
higher rates of fructose consumption are recorded. The accuracy
of our computation of fructose intake is in keeping with the
industrial fructose intake reported in the Italian population [4],
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the LOOK Ahead study consuming P15 g/day of fructose
(high-fructose consumers), a fructose challenge identiﬁed
metabolic abnormalities potentially responsible for NAFLD
progression [6]. This threshold was observed in most of our cases
with ﬁbrosis, and the higher industrial fructose intake was the
major source of difference between cases with advanced vs. mild
hepatic ﬁbrosis. When industrial fructose intake as continuous
variable was replaced in the model by industrial fructose
as categorical variable, 14/25 patients consuming P8 g/day
industrial fructose had F3-F4 ﬁbrosis vs. 18/89 in the group with
lower intake (p = 0.01).
Thirdly, Kitson et al. remark the lack of association between
severe liver ﬁbrosis and both insulin resistance (IR) and steatosis
in this speciﬁc population. In the present series, steatosis was
linked to ﬁbrosis at both univariate and multivariate analysis.
Both IR and steatosis, the phenotypic hepatic expression of IR,
are risk factors for ﬁbrosis; they both might play an important
role in ﬁbrosis progression and are likely to be variably combined
in different settings [7,8]. As to the possible reason(s) why indus-
trial, not fruit fructose intake, is associated with the severity of
liver ﬁbrosis in CHC, several tentative hypotheses may be
suggested. In fresh fruit the deleterious effects of fructose might
be counterbalanced by the positive effects of other nutrients (e.g.,
ﬁbers) and antioxidants, not present in industrial fructose. In
processed food, the glucose of high-fructose corn syrup might
accelerate fructose absorption, making industrial sugars
unhealthy. Finally, even if the link between industrial fructose
and the clinico-pathological features (i.e., liver ﬁbrosis and obes-
ity) was independent of energy intake on a statistical basis, we
cannot rule out a pivotal role of calories and/or of a less healthy
diet and lifestyle in the reported association, considering that
higher amounts of industrial fructose were associated with
high-calorie diets.
Hence we are conﬁdent that our study provides reliable evi-
dence, albeit of an associative nature. Further research is clearly
needed to provide external validation and to eventually elucidate
the pathophysiological basis, aiming to a healthy diet as an addi-
tional tool to manage patients with HCV-induced chronic liver
disease.14 vol. 60 j 676–683 677
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To close the stable door before the horse has bolted
To the Editor:
We read with interest the studies by Fagundes and colleagues [1],
Piano and colleagues [2] and the accompanying editorial [3].
Both studies evaluated large numbers of patients with cirrhosis
(375 and 233, respectively) and assessed the impact of acute kidney
injury (AKI), assessedbothbyAKIN criteria and themore conventional
ﬁnding of a creatinine level ofP1.5 mg/dl. Piano and colleagues only
included patients with hospital acquired AKI, thus excluding patients
who already had renal impairment on admission. In this study, all
patients had ascites, while in the study by Fagundes and colleagues
this was present in two thirds. In both studies, patients with stage 1
AKI with a peak creatinine <1.5 mg/dl did not have an increasedmor-
tality as compared to patients without AKI. The accompanying edito-
rial therefore suggests the conclusion that stage 1 AKI with a peak
creatinine of <1.5 mg/dl is a benign condition.
The importance of renal failure in cirrhosis is well established.
It increases the risk of dying 7-fold and carries a 1 month mortal-
ity of up to 50% [4], an impact on the natural history of a magni-
tude similar to that of bacterial infections [5]. Creatinine as an
indicator of renal function is an essential component of prognos-
tic scores such as MELD and UKELD. Both the stage of AKI and the
peak creatinine level are associated with increased mortality [6].
Tsien and colleagues [7] recently published a prospective study
on 90 outpatients with cirrhosis and ascites. Episodes of AKI (as
per AKIN criteria) were common, and the mean peak creatinine
value was within normal laboratory values. Importantly, patients
with an episode of AKI had decreased survival on follow up.
While widely used, creatinine remains an imperfect marker of
renal function in cirrhosis. Not only can high levels of bilirubin inter-
fere with creatinine measurements, but levels also correlate with
total musclemass, which is oftenmarkedly reduced in patients with
cirrhosis and ascites [8]. As a consequence, baseline creatinine levels
in patients with cirrhosis are frequently substantially lower than the
upper limit of normal used by laboratories, and substantial increases
in creatinine levelmay not exceed the ‘‘normal values’’ andmay thus
not be spotted by the non-hepatologist.
We would therefore like to disagree with the conclusion that
stage 1 AKI with a peak creatinine of <1.5 mg/dl is a ‘‘benign’’
condition. Both Fagundes’ and Piano’s study had standard inter-
ventions for patients whose creatinine increased (even if below
1.5 mg/dl), and these measures were implemented rapidly since
all patients were in hospital. These included such crucial mea-
sures as withdrawal of diuretics and nephrotoxic drugs, diagnosis
and treatment of bacterial infections and ﬂuid challenges with
crystalloids or albumin. In Tien’s study, blood tests were taken
every 4–6 weeks but clinical evaluation for assessment of AKI
only occurred every 4 months – this raises the question whether
interventions in patients with increasing renal markers were not
carried out in a similarly timely fashion. This is in line with a
recently published trial reporting improved survival in patients
with cirrhosis and ascites who were allocated to closely moni-
tored outpatient management under the care of a specialised
clinical team at a dedicated Hepatology centre [9].
In our opinion, the correct conclusion from the current evi-
dence should be that stage 1 AKI with a peak creatinine of
<1.5 mg/dl in patients with cirrhosis is a potentially benign con-
dition if promptly treated and correctly managed. If ignored and
untreated, it is likely to progress to higher stages of AKI and carry
an increased mortality. Our vigilance should therefore be aimed
at the timely detection of renal impairment in patients with
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